Search

everythinglearnresearchcommunity

for

Search:↓

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Hair follicles have a more inactive cell cycle than other skin cells, which may help develop targeted therapies for skin diseases and cancer.

Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.

HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

Cancer development is like natural selection, involving mutated cells and environmental factors.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Certain interactions help prepare the androgen receptor for pairing and activation, which is important for its role in development and disease.

Removing Sprouty genes in mice causes various hormone-related issues but does not increase cancer risk by one year of age.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Key genes linked to hair growth and cancer were identified in hairless mice.

A new method, iSiMPRe, effectively identifies key protein regions in cancer genes, highlighting potential drug targets.

A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.

Combined finasteride and anastrozole therapy effectively treats BPH, influenced by hormone imbalances and genetics.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

TMPRSS2 is crucial for COVID-19 infection and is a potential target for treatment.

We need better ways to test and understand SARMs to make safer and more effective treatments.

Melatonin receptors, found in many body parts, can help treat various diseases like depression and diabetes due to their effects on inflammation, tumor progression, sleep disorders, and body mass regulation.

Obesity increases the risk of skin infections, inflammatory conditions, and melanoma, but not basal cell carcinoma.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

Mutations in the AR gene cause hair thinning and loss.